PET Imaging in Neuro-Oncology: An Update and Overview of a Rapidly Growing Area.
Fiche publication
Date publication
février 2022
Journal
Cancers
Auteurs
Membres identifiés du Cancéropôle Est :
Pr VERGER Antoine
Tous les auteurs :
Verger A, Kas A, Darcourt J, Guedj E
Lien Pubmed
Résumé
PET plays an increasingly important role in the management of brain tumors. This review outlines currently available PET radiotracers and their respective indications. It specifically focuses on F-FDG, amino acid and somatostatin receptor radiotracers, for imaging gliomas, meningiomas, primary central nervous system lymphomas as well as brain metastases. Recent advances in radiopharmaceuticals, image analyses and translational applications to therapy are also discussed. The objective of this review is to provide a comprehensive overview of PET imaging's potential in neuro-oncology as an adjunct to brain MRI for all medical professionals implicated in brain tumor diagnosis and care.
Mots clés
FDG, PET, amino acid, brain metastases, glioma, meningioma, neuro-oncology, peptide radionuclide therapy, primary central nervous system lymphoma, somatostatin
Référence
Cancers (Basel). 2022 Feb 22;14(5):